Business Wire

IMMERVISION

Share
Immervision Introduces JOYCE, the First Humanoid Robot with Intelligent Vision Developed by the Computer Vision Community

Immervision , the Montreal-based leader in wide-angle intelligent vision, introduces JOYCE , the first humanoid robot developed by the computer vision community to help machines gain human-like perception and beyond.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005563/en/

Watch the video: https://vimeo.com/458617443

The purpose of JOYCE is to further advance computer vision technologies by inviting the community to help JOYCE gain a better understanding of her environment by upgrading her optics, sensors and AI algorithms.

To support the realization of this complex task, Immervision is also unveiling the JOYCE Development Kit for engineers and AI developers. This “JOYCE IN A BOX” development kit is equipped with three ultra-wide-angle panomorph cameras calibrated to give 2D hemispheric, 3D stereoscopic hemispheric or full 360 x 360 spherical capture and viewing of the environment. It uses data-In-picture technology so that each of her video frames can be enriched with data from a wide array of sensors providing contextual information to AI and neural networks, computer vision and SLAM algorithms to help increase her visual perception.

Moreover, JOYCE will be streaming live so that people can, not only follow the evolution of her capabilities, but also look through her eyes while she travels around the world, skydives, visits a business conference or a computer vision lab.

JOYCE stems from the Immervision InnovationLab which mission is to accelerate the emergence of new innovative solutions and help build the next generation of intelligent vision systems for a wide range of industry devices.

“At Immervision, we strongly believe in the value of bringing together the computer vision community to break down the silos that are slowing the innovation cycle. Instead, let’s push forward the boundaries of machine perception through cross-pollination. We believe that JOYCE will help develop extremely innovative solutions to resolve complex industry challenges,” said Pascale Nini, President and CEO of Immervision.

Potential use cases include:

  • Enhance the performance of smart home devices such as vacuum cleaners, lighting systems and home appliances.
  • Improve optics technologies to ensure driver safety in assisted driving and autonomous cars.
  • Improve fire fighters ability to detect people and objects over trees and see through smoke.
  • Improve medical diagnostics to better identify cancer tumors or other conditions on a CT scan.
  • Help identify early signs of crop diseases, and many more.

To follow JOYCE’s progress and collaboration within the community, visit her at JOYCE.VISION and follow her on her social channels.

About Immervision

Immervision enables intelligent vision in any device. Our Deep Seeing technology and renowned experts in wide-angle optical design and image processing enable smart devices with superhuman eyes to capture high quality visual and contextual data. We invent, customise and license wide-angle lenses and imaging software technology for AI, machine vision and user applications, from capture to display, in the mobile, automotive, robotics, security, and other industrial and consumer product industries. www.immervision.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release

Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio

SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release

Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon

European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye